Noemi Reguart· @NReguart · X·· 14 小时前评分70
正文 · 原文
Impressive results from phase III DeLLphi-305 at #ESMO26 @sands_jacob: Adding tarlatamab to durvalumab maintenance in ES-SCLC 1-y OS nearly 80%!!!
🔹 OS: 21.1 vs 12.7 mo (HR 0.42)
🔹 PFS: 7.4 vs 1.9 mo (HR 0.34)
A standing ovation!” 👏👏👏👏A major step forward for SCLC! @NEJM
76 浏览 · 2 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Noemi Reguart · x.com